Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Zymeworks Inc. is a biotechnology company specializing in developing multifunctional, antibody-based therapeutics for cancer and autoimmune diseases. Its platforms enable precise engineering of bispecific, multispecific, and antibody-drug conjugates. The company partners globally to advance innovative treatments, leveraging proprietary technologies to address unmet medical needs and generate revenue through licensing, milestone payments, and royalties. Its pipeline includes clinical and preclinical candidates targeting high-value cancer indications.
This description was generated via AI from an annual report. Updated about 1 year ago.